Novo Nordisk has launched its once-daily Wegovy weight-loss pill in the US at a lower price than injections.
The drug is the first and only GLP-1 pill on the market and was approved shortly before Christmas.
Cash-paying patients can access the starting dose for $149 a month, far below injectable prices.
The pill offers a needle-free option and is expected to broaden patient appeal.
Novo aims to regain market share amid strong competition from Eli Lilly.
Shares rose after the launch despite a sharp yearly decline.
The pill is available through major US pharmacies and telehealth providers.
UK approval is under review and a decision is expected later this year.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Price War
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment